Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease

Patients with inflammatory bowel disease (IBD) treated with biologic and/or immunosuppressant drugs are at increased risk for opportunistic infections. Seroprevalence studies can confirm the diagnosis of SARS-CoV-2 infections as well as the associated risk factors. This is a descriptive study which...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Arranz, M. D., García-Ramírez, L., Hernandez-Perez, M., Montero Vega, D., Martín-Arranz, E., Sánchez-Azofra, M., Poza Cordon, J., Rueda Garcia, J. L., Noci Belda, J., Verges Martínez-Meco, T., Blanco San Miguel, P., Suarez Ferrer, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148621/
https://www.ncbi.nlm.nih.gov/pubmed/37120662
http://dx.doi.org/10.1038/s41598-023-33402-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148621/
https://www.ncbi.nlm.nih.gov/pubmed/37120662
http://dx.doi.org/10.1038/s41598-023-33402-w

Ejemplares similares